NCT05004116View on ClinicalTrials.gov

A Study of Repotrectinib in Combination With Chemotherapy in Children and Young Adults With Solid Tumor Cancer

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

77

Participants

Timeline

Start Date

August 9, 2021

Primary Completion Date

August 31, 2028

Study Completion Date

August 31, 2028

Conditions
Advanced CancerMetastatic Solid Tumor
Interventions
DRUG

Repotrectinib

TPX-0005 (Repotrectinib) will be taken orally twice daily in 28-day cycles without regard to food and will be administered orally before administration of irinotecan and temozolomide (exception: C1, TPX-0005 (Repotrectinib) will be administered once daily x 14 days, then twice daily D15-D28).

DRUG

Irinotecan and temozolomide

Irinotecan and temozolomide will be given as per institutional standard.

Trial Locations (1)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER